• Pentixapharm expects first-patient enrollment in its pivotal PANDA Phase 3 trial in the first quarter of 2027, with no material timetable changes.
• The FDA raised no objections to the August 2026 protocol; a central US ethics board cleared the study.
• The trial targets about 325 patients, with more than 10 US study sites selected.
• FDA authorization to conduct the trial came in June 2026, followed by fast-track designation in July.
• Third-quarter financial results will be presented alongside a PANDA progress update at a November 12, 2026, webcast at 3 p.m. CET.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.